Scarica l'app Stockscreener
0.1293
4.61%
0.0057
Precedente Chiudi:
$0.1236
Aprire:
$0.132
Volume 24 ore:
32.44M
Relative Volume:
2.30
Capitalizzazione di mercato:
$5.50M
Reddito:
-
Utile/perdita netta:
$-18.61M
Rapporto P/E:
-0.0129
EPS:
-10.05
Flusso di cassa netto:
$-13.91M
1 W Prestazione:
+8.75%
1M Prestazione:
-11.44%
6M Prestazione:
-98.80%
1 anno Prestazione:
-99.88%
Intervallo 1D:
$0.1275
$0.145
Intervallo di 1 settimana:
$0.1025
$0.145
Portata 52W:
$0.0955
$135.00
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Nome
Cns Pharmaceuticals Inc
Settore
Industria
Telefono
1-800-946-9185
Indirizzo
2100 WEST LOOP SOUTH, HOUSTON
Confronta CNSP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| CNSP | 0.1298 | 5.50M | 0 | -18.61M | -13.91M | -10.05 |
| VRTX | 449.87 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.58 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 595.99 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.18 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.15 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-12-28 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-08-24 | Iniziato | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Borsa (CNSP) Ultime notizie
CNS Pharmaceuticals (NASDAQ: CNSP) to Present Berubicin Trial Update at Society for Neuro-Oncology Annual Meeting - Barchart
CNS Pharmaceuticals (NASDAQ: CNSP) Advances Glioblastoma Treatment With Berubicin - Barchart
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024) - AccessWire
CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results - AccessWire
CNS Pharmaceuticals Completes 252-Patient Enrollment in Pivotal Brain Cancer Study | CNSP Stock News - StockTitan
CNS Pharmaceuticals Inc (CNSP) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires New Stake in CNS Pharmaceuticals Inc - GuruFocus.com
CNS Pharmaceuticals: Financial Results and Strategic Moves - TipRanks
CNS Pharmaceuticals’ $3 Million Common Stock Offering - Global Legal Chronicle
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment - AccessWire
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights Berubicin’s Potential During KOL Connect Event - Barchart
CNS Pharmaceuticals Receives Temporary Exception from NASDAQ Regarding Minimum Bid Price Requirement - Defense World
CNS Pharmaceuticals granted Nasdaq compliance extension By Investing.com - Investing.com South Africa
CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - Yahoo Finance
CNS Pharmaceuticals granted Nasdaq compliance extension - Investing.com
CNSPCNS Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Stocks Under Ten Cents to Watch in October 2024 CNSP, QLGN, AKTS, CBDW, RJDG - Financial Content
CNS Pharmaceuticals faces NASDAQ delisting over price rule By Investing.com - Investing.com Australia
CNS Pharmaceuticals secures $3 million in registered direct offering - Investing.com
CNS Pharmaceuticals secures $3 million in registered direct offering By Investing.com - Investing.com UK
CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - AccessWire
CNS Pharmaceuticals faces NASDAQ delisting over price rule - Investing.com
Stock Performance Spotlight: Cns Pharmaceuticals Inc (CNSP) Ends the Day at 0.12, Up by 0.77 - The Dwinnex
Can you still get a good price for Cns Pharmaceuticals Inc (CNSP) Shares at this point? - US Post News
CNS Pharmaceuticals (NASDAQ: CNSP) Management Participates In Virtual Investor KOL Connect Segment - Barchart
Cns Pharmaceuticals Inc (CNSP-Q) QuotePress Release - The Globe and Mail
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at the 24th Annual Biotech in Europe Forum - MSN
It is Poised to be a Bull Market for Cns Pharmaceuticals Inc (CNSP) - SETE News
CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment - BioSpace
Ladenburg Thalmann gives a Neutral recommendation for Cns Pharmaceuticals Inc (CNSP) - Knox Daily
Cns Pharmaceuticals Inc (CNSP) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC - StockTitan
A stock that deserves closer examination: Cns Pharmaceuticals Inc (CNSP) - US Post News
Ratio Examination: Cns Pharmaceuticals Inc (CNSP)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference - The Manila Times
Wall Street analysts’ outlook for Cns Pharmaceuticals Inc (CNSP) - SETE News
Cns Pharmaceuticals Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle
Titan Medical Inc (TMD-T) QuotePress Release - The Globe and Mail
Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024 - The Manila Times
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference - ForexTV.com
Cns Pharmaceuticals Inc (CNSP)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Examining Cns Pharmaceuticals Inc (CNSP) stock is warranted - US Post News
CNS Therapeutics Market 2024 Share, Growth Forecast and Industry Outlook 2032 | Eli Lilly and Co. - 대구포스트
CNS Pharma (NASDAQ:CNSP) Stock Quotes, Forecast and News Summary - Benzinga
A new trading data show Cns Pharmaceuticals Inc (CNSP) is showing positive returns. - SETE News
Do investors need to be concerned about Cns Pharmaceuticals Inc (CNSP)? - US Post News
CNS (Central Nervous System) Therapeutics Market 2024 Size, Status and Global Outlook 2031 - Newstrail
CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum - AccessWire
Ratio Review: Analyzing Cns Pharmaceuticals Inc (CNSP)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Cns Pharmaceuticals Inc Azioni (CNSP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cns Pharmaceuticals Inc Azioni (CNSP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Evans Carl Anthony | Director |
Feb 01 '24 |
Buy |
0.30 |
33,333 |
10,000 |
33,458 |
| Downs Christopher | Chief Financial Officer |
Feb 01 '24 |
Buy |
0.30 |
66,666 |
20,000 |
103,438 |
| Climaco John M | Chief Executive Officer |
Feb 01 '24 |
Buy |
0.30 |
166,666 |
50,000 |
215,676 |
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):